PAM484

Macimorelina en diagnóstico del déficit de hormona del crecimiento

MEDICAMENTOS EN ESPAÑA

Valoración Macimorelina

▼ GHRYVELIN® (Atnahs Pharma Netherlands BV)

INNOVACIÓN MODERADA (**) Aporta algunas mejoras, pero no implica cambios sustanciales en la terapéutica estándar.

Grupo Terapéutico (ATC) : ): V04CD06. PRUEBAS DE FUNCIÓN HIPOFISARIA.

Indicaciones autorizadas: diagnóstico del déficit de hormona del crecimiento en adultos.

Bibliografía Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Ficha técnica de Ghryvelin® (macimorelina). 2024. Disponible en: https://cima.aemps.es/cima/dochtml/ft/1181337001/ FT_1181337001.html. Devesa J. The Complex World of Regulation of Pituitary Growth Hormone Secretion: The Role of Ghrelin, Klotho, and Nesfatins in It. Front Endocrinol (Lausanne). 2021; 12: 636403. DOI: 10.3389/ fendo.2021.636403. European Medicines Agency (EMA). Ghryvelin®. European Public Assessment Report (EPAR). 2019. EMA/CHMP/845216/2018. Disponible en: https://www.ema.europa.eu/en/documents/ assessment-report/ghryvelin-previously-macimorelin-aeterna zentaris-epar-public-assessment-report_en.pdf. Garcia JM, Biller BMK, Korbonits M, Popovic V, Luger A, Strasburger CJ et al. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab. 2018; 103(8): 3083-93. DOI: 10.1210/jc.2018-00665. Garcia JM, Swerdloff R, Wang C, Kyle M, Kipnes M, Biller BM et al. Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab. 2013; 98(6): 2422-9. DOI: 10.1210/jc.2013-1157.

Hamrahian AH, Yuen KC, Gordon MB, Pulaski-Liebert KJ, Bena J, Biller BM. Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study. Pituitary. 2016; 19(3): 332-41. DOI: 10.1007/s11102-016-0712-7. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(6): 1587-609. DOI: 10.1210/jc.2011-0179. Ratku B, Sebestyén V, Erdei A, Nagy EV, Szabó Z, Somodi S. Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile. Pituitary. 2022; 25(2): 211-28. DOI: 10.1007/s11102-022-01207-1. Tanriverdi F, Kelestimur F. Classical and non-classical causes of GH deficiency in adults. Best Pract Res Clin Endocrinol Metab. 2017; 31(1): 3-11. DOI: 10.1016/j.beem.2017.02.001. Yuen KC. Glucagon stimulation testing in assessing for adult growth hormone deficiency: current status and future perspectives. ISRN Endocrinol. 2011; 2011: 608056. DOI: 10.5402/2011/608056.

659